Literature DB >> 15746048

Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.

Tomás Alvaro1, Marylène Lejeune, Ma Teresa Salvadó, Ramón Bosch, Juan F García, Joaquín Jaén, Alison H Banham, Giovanna Roncador, Carlos Montalbán, Miguel A Piris.   

Abstract

PURPOSE: Recent studies of Hodgkin's lymphoma (HL) have suggested that the presence of regulatory T cells in the reactive background may explain the inhibition of the antitumoral host immune response observed in these patients. This study aimed to assess the relevance of regulatory T cells and CTLs present in the background of HL samples in the prognosis of a series of classic HL (cHL) patients. EXPERIMENTAL
DESIGN: Expression of granzyme B and TIA-1 (markers for CTL) and FOXP3 (a marker for regulatory T cells) were evaluated independently by immunohistochemistry in tissue microarrays of 257 cHL patients and correlated with patient outcome.
RESULTS: The combined influence of the presence of FOXP3(+) and TIA-1(+) cells distinguished three risk groups of patients with 5-year overall survival of 100%, 88%, and 73%. The presence of a small number of FOXP3(+) cells and a high proportion of TIA-1(+) cells in the infiltrate represent an independent prognostic factor that negatively influenced event-free survival and disease-free survival in cHL. Compared with the features at diagnosis, relapsed samples tended to have more TIA-1(+) cells and a lower proportion of FOXP3(+) cells in the reactive background.
CONCLUSIONS: These data suggest that low infiltration of FOXP3(+) cells in conjunction with high infiltration of TIA-1(+) cells in cHL may represent biological markers predicting an unfavorable outcome. Moreover, the variation of these markers over the course of the disease implies a possible role for them in the progression of HL cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15746048     DOI: 10.1158/1078-0432.CCR-04-1869

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  136 in total

1.  B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.

Authors:  Dong Hua; Jing Sun; Yong Mao; Lu-Jun Chen; Yu-Yu Wu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Early effects of low dose C ion or x-ray irradiation on peripheral blood lymphocytes of patients with alimentary tract cancer.

Authors:  Yingtai Chen; Xuezhong Chen; Yumin Li; Hong Zhang; Yi Xie; Xiaowei Zhang; Huizi Ren; Yanling Wang; Shiqi Liao; Mingyan He; Jinyu Ren; Jieyu Zhang; Xiadong Zhou; Tongzhang Zheng; Briseis A Kilfoy; Yawei Zhang
Journal:  Dose Response       Date:  2010-08-02       Impact factor: 2.658

3.  Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma.

Authors:  Beatriz Sánchez-Espiridión; Ana M Martin-Moreno; Carlos Montalbán; L Jeffrey Medeiros; Francisco Vega; Anas Younes; Miguel A Piris; Juan F Garcia
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

4.  JPEG2000 for automated quantification of immunohistochemically stained cell nuclei: a comparative study with standard JPEG format.

Authors:  Marylène Lejeune; Carlos López; Ramón Bosch; Anna Korzyńska; Maria-Teresa Salvadó; Marcial García-Rojo; Urszula Neuman; Łukasz Witkowski; Jordi Baucells; Joaquín Jaén
Journal:  Virchows Arch       Date:  2010-11-18       Impact factor: 4.064

5.  Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma.

Authors:  Peter Kamper; Knud Bendix; Stephen Hamilton-Dutoit; Bent Honoré; Jens R Nyengaard; Francesco d'Amore
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

Review 6.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

Review 7.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

Review 8.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.